Following the recent transfer to a new analyst, we take a closer look at Ansell’s (ASX: ANN) moat, capital allocation and uncertainty ratings, in addition to its key growth drivers. Critically, we reassess what this means for our long-term earnings assumptions and thesis.

Why it matters: We assign Ansell a no-moat rating, downgrading from its previous narrow. We view some of the company, including the Hyflex brand, and parts of healthcare, as moaty due to user-led brand power. However, we are not convinced that most of the company has enough brand strength to maintain pricing power.

  • Barriers to entry are relatively low, with all players subject to the same regulations and able to purchase the same or similar material inputs. We believe large competitors, such as Honeywell (PIP), 3M, Halyard Health (Owens & Minor), and Cardinal Health, also have strong brand power.
  • We maintain our Medium Uncertainty and Exemplary Capital Allocation ratings. We view the company’s capital allocation track record as exceptional, with acquisitions supporting its strategy to improve competitive positioning by entering niche categories. The Kimberley-Clark PPE acquisition in 2024 is the latest example.

The bottom line: We cut our fair value estimate on no-moat Ansell by 9% to AUD 32 per share. The downgrade is due to lower margins and reduced long-term expectations. Shares are fairly valued.

  • Our fiscal 2030 midcycle EBIT margin assumption is 16%, 160 basis points lower than previously. The modest 200 basis points of margin growth from fiscal 2025 levels reflects improved operating leverage in both healthcare and industrial, and a mix shift toward specialized, higher-margin surgical and cleanroom products.
  • We estimate a slightly higher revenue growth rate, averaging 4% over our explicit forecast period, up from 3% previously, on a more bullish view on healthcare. We expect a mix shift to more specialized, and therefore more expensive, products, particularly for customers in emerging markets.

Downgrading Ansell to no-moat rating rrom narrow, as brand power doesn’t always mean pricing power

Ansell’s strategic focus is on growing market share in niche markets across industrial and healthcare settings. We think this strategy is appropriate, given a less competitive environment in niche markets, where product innovation and regulatory requirements raise barriers to entry, and an ability to achieve better margins from these sales.

Each market is reasonably fragmented, and Ansell’s market share varies by subsegment, but it has consistently held the highest or second-highest global market share in its key product categories. Main competitors are Honeywell (PIP), 3M, and Globus (UK) in industrial, and Cardinal Health, Honeywell, and Halyard Health (Owens & Minor) in healthcare.

Revenue is split approximately 50/50 between healthcare and industrial products. Industrial is exposed to global manufacturing cycles, and the US purchasing managers’ index is a key leading indicator of Ansell’s industrial revenue growth. Revenue from the healthcare segment is more defensive, with low cyclical exposure.

We estimate the global protective wear market to grow in the low single digits, driven by the positive trends toward improved workplace safety, but partially offset by increasing automation. Growth opportunities include emerging markets, where users are shifting from commoditized products to niche alternatives.

In the midterm, we expect capital investment to be weighted toward the healthcare segment to support its higher-growth businesses. Cleanroom and surgical are fast-growing categories where contamination prevention is critical. We observe that Ansell is one of only a few players serving the cleanroom niche, with its market share position cemented by the Kimberly-Clark PPE acquisition in 2024. We estimate cleanroom and surgical contributing about 30% of midcycle sales.

Ansell’s margins are sensitive to key input prices, including yarn, butadiene for nitrile rubber gloves, and natural rubber for latex gloves. The approximately five-month lead time from raw material procurement to product sale provides Ansell with a window to pass through increases in input costs, if necessary, and the company has historically been able to do so.

Bulls say

  • Expansion in cleanroom and surgical, a niche where Ansell’s products are more differentiated, earns materially higher margins than its other businesses, supporting group margin growth.
  • Ansell has demonstrated good capital allocation skills and has successfully integrated acquisitions and consolidated the product portfolio into key brands.
  • The company has balance sheet capacity for acquisitions and share buybacks, both of which could enhance shareholder returns.

Bears say

  • Cost pressures such as tariffs and supply chain disruptions weigh on operations, without certainty that price pass-throughs will succeed.
  • Ansell sells primarily through distributors, where it is one of many glove suppliers in some categories. This limits its visibility into and influence over end-customer purchasing decisions.
  • Although Ansell is a leading supplier by market share, it still competes with many large competitors with reputable brands, that could take market share through new products or targeting the same customers.